Abstract
Neuropeptide Y (NPY) is a 36-amino-acid peptide that attenuates seizure activity following direct infusion or adeno-associated virus (AAV)-mediated expression in the central nervous system. However, NPY activates all NPY receptor subtypes, potentially causing unwanted side effects. NPY13-36 is a C-terminal peptide fragment of NPY that primarily activates the NPY Y2 receptor, thought to mediate the antiseizure activity. Therefore, we investigated if recombinant adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 could alter limbic seizure sensitivity. Rats received bilateral piriform cortex infusions of AAV vectors that express and constitutively secrete full-length NPY (AAV-FIB-NPY) or NPY13-36 (AAV-FIB-NPY13-36). Control rats received no infusion, as we have previously shown that vectors expressing and secreting reporter genes like GFP (AAV-FIB-EGFP), as well as vectors expressing peptides that lack secretion sequences (AAV-GAL) have no effect on seizures. One week later, all animals received kainic acid (10 mg kg−1, intraperitoneally), and the latencies to wet dog shakes and limbic seizure behaviors were determined. Although both control and vector-treated rats developed wet dog shake behaviors with similar latencies, the latencies to class III and class IV limbic seizures were significantly prolonged in both NPY- and NPY13-36-treated groups. Thus, AAV-mediated expression and constitutive secretion of NPY and NPY13-36 is effective in attenuating limbic seizures, and provides a platform for delivering therapeutic peptide fragments with increased receptor selectivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McCown TJ . Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 2006; 14: 63–68.
Klugmann M, Symes CW, Leichtlein CB, Klaussner BK, Dunning J, Fong D et al. AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci 2005; 28: 347–360.
Haberman RP, Samulski RJ, McCown TJ . Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 2003; 9: 1076–1080.
Freese A, Kaplitt MG, O'Connor WM, Abbey M, Langer D, Leone P et al. Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy. Epilepsia 1997; 38: 759–766.
Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D, Ravizza T, Richichi C et al. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience 2002; 110: 237–243.
Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004; 24: 3051–3059.
Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ . Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003; 18: 2087–2092.
Colmers WF, Klapstein GJ, Fournier A, St-Pierre S, Treherne KA . Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br J Pharmacol 1991; 102: 41–44.
Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R . Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol 2000; 78: 116–125.
Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E et al. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol 2000; 129: 1075–1088.
Greber S, Schwarzer C, Sperk G . Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br J Pharmacol 1994; 113: 737–740.
Lin EJ, Young D, Baer K, Herzog H, During MJ . Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 2006; 47: 773–780.
El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger AG, Sperk G et al. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci 2005; 22: 1417–1430.
El Bahh B, Cao JQ, Beck-Sickinger AG, Colmers WF . Blockade of neuropeptide Y(2) receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246. Br J Pharmacol 2002; 136: 502–509.
Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G . Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 2001; 21: 5804–5812.
Kofler N, Kirchmair E, Schwarzer C, Sperk G . Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci Lett 1997; 230: 129–132.
Schwarzer C, Kofler N, Sperk G . Up-regulation of neuropeptide Y-Y2 receptors in an animal model of temporal lobe epilepsy. Mol Pharmacol 1998; 53: 6–13.
Vezzani A, Moneta D, Mule F, Ravizza T, Gobbi M, French-Mullen J et al. Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures. Epilepsia 2000; 41 (Suppl 6): S115–S121.
Vezzani A, Rizzi M, Conti M, Samanin R . Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors. J Nutr 2000; 130: 1046S–1048S.
Frush DP, McNamara JO . Evidence implicating dentate granule cells in wet dog shakes produced by kindling stimulations of entorhinal cortex. Exp Neurol 1986; 92: 102–113.
Racine RJ . Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281–294.
Acknowledgements
We thank Julie Hamra for expert technical assistance. The study was supported by NIH grant NINDS NS 35633 to TJM.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Foti, S., Haberman, R., Samulski, R. et al. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther 14, 1534–1536 (2007). https://doi.org/10.1038/sj.gt.3303013
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3303013
Keywords
This article is cited by
-
Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures
Gene Therapy (2023)
-
A Molecular Approach to Epilepsy Management: from Current Therapeutic Methods to Preconditioning Efforts
Molecular Neurobiology (2015)
-
Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus
Gene Therapy (2013)
-
Progress in gene therapy for neurological disorders
Nature Reviews Neurology (2013)
-
Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment
Neuropsychopharmacology (2010)